CAS 20675-51-8​​ CBC,99%

Cannabichromene (CBC) (CAS 20675-51-8)​​ is a non-psychoactive cannabinoid recognized for its potential synergistic role in the "entourage effect" and its distinct pharmacological profile. Unlike THC, it does not bind strongly to CB1 receptors but interacts with other targets such as TRPV and serotonin receptors, contributing to its studied anti-inflammatory, antimicrobial, and neurogenesis-promoting properties. Though typically found in low concentrations in cannabis cultivars, its emerging therapeutic potential makes it a compound of growing interest in neurological and inflammatory disorder research.  

Cannabigerol  ​​(CBG) (CAS 25654-31-3)​​ is a non-psychoactive cannabinoid often referred to as the "mother cannabinoid" or "stem cell cannabinoid" because it serves as the direct biosynthetic precursor to other major cannabinoids like THC, CBD, and CBC in the cannabis plant. Though typically present in low concentrations in most cultivars, it exhibits a broad pharmacological profile, interacting with CB1, CB2, and other receptors, and is researched for its potential anti-inflammatory, antimicrobial, and neuroprotective properties. Its critical role in cannabinoid biosynthesis and its emerging therapeutic promise make it a high-value compound for both agricultural and pharmaceutical development.

Cannabinol  (CAS 521-35-7)​​ is a mildly psychoactive cannabinoid formed primarily through the oxidative degradation of tetrahydrocannabinol (THC), often accumulating in aged cannabis material. It exhibits a unique pharmacological profile characterized by a higher affinity for CB2 receptors than CB1, contributing to its potential therapeutic applications in sleep regulation, pain relief, and as an anti-inflammatory agent. While its psychoactive effects are significantly weaker than THC, its role as a marker for cannabis aging and its emerging bioactivity make it a compound of growing interest in medicinal and analytical research.

Cannabidivarol (CAS 24274-48-4)​​ is a non-psychoactive propyl analogue of cannabidiol (CBD), distinguished by its shorter three-carbon side chain instead of CBD’s pentyl chain. This structural variation influences its pharmacological profile, enhancing its research relevance as a potential therapeutic agent, particularly for its noted anticonvulsant properties and emerging applications in treating neurological disorders such as epilepsy. As a minor cannabinoid, it also serves as a critical tool for studying structure-activity relationships within the endocannabinoid system.

Cannabigerolic Acid (CAS 25555-57-1)​​ is the fundamental biogenic precursor and "mother cannabinoid" in the cannabis plant, serving as the central biosynthetic intermediate from which other major cannabinoids—such as THCA, CBDA, and CBCA—are enzymatically derived. This carboxylic acid-containing compound exhibits inherent bioactive properties, including potential anti-inflammatory and neuroprotective effects, and is increasingly studied for its role in early-stage cannabis biosynthesis and its direct therapeutic applications in medicinal research.  

Cannabivarol (CAS 33745-21-0) is a cannabinoid derivative with potential analgesic and neuroprotective properties. Its structural complexity and lipophilicity present challenges in drug development but also offer opportunities for targeted therapeutic applications.